Aptose Biosciences Inc.
APTOF evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for APTOF—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · APTOF
Aptose Biosciences Inc. is a clinical-stage biotechnology company developing targeted therapies for hematologic malignancies, currently facing severe liquidity constraints and a risk of imminent bankruptcy.
Key risk: Imminent bankruptcy risk
Market Cap
$4.3M
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Financial data as of Mar 31, 2026.
Tracking 1 clinical trial for Aptose Biosciences Inc..
Aptose Biosciences Inc. is a clinical-stage biotechnology company developing targeted therapies for hematologic malignancies, currently facing severe liquidity constraints and a risk of imminent bankruptcy.
- Aptose is an early-stage development company with no current revenues from drug candidates [sec_mda · as of 2026-03-31].
- As of 2026-03-31, the company reported a net loss of $7.6M and a shareholders' deficit of $34.7M [sec].
- The company's lead program, tuspetinib, is being evaluated in the TUSCANY study, with R&D expenses for tuspetinib decreasing to $7.9M in 2025 from $9.6M in 2024 [sec_mda · as of 2026-03-31].
- Aptose has disclosed a risk of imminent bankruptcy and needs substantial funding immediately to continue operations [sec_mda · as of 2026-05-13].
- The TSX has deferred a delisting decision for the company's securities until no later than April 17, 2026 [sec_mda · as of 2026-03-31].
What works
- The company has reduced cash used in operating activities to $22.0M in 2025 from $36.0M in 2024, indicating cost management efforts [sec_mda · as of 2026-03-31].
- Aptose has exclusive global rights to tuspetinib under a licensing agreement with Hanmi, with potential milestone and royalty payments tied to development and sales [sec_mda · as of 2026-03-31].
- The company maintains cash at high-credit quality institutions and uses short-term investments for excess cash [sec_mda · as of 2026-03-31].
What to weigh
- Aptose has a shareholders' deficit of $34.7M as of 2026-03-31, indicating negative equity [sec].
- The company has disclosed a risk of imminent bankruptcy and requires immediate substantial funding to continue operations [sec_mda · as of 2026-05-13].
- The TSX has deferred a delisting decision, creating uncertainty about the company's listing status [sec_mda · as of 2026-03-31].
- Aptose has no current revenues and relies on equity financing and other sources to fund operations [sec_mda · as of 2026-03-31].
From the filings
Quoted directly from source documents.
Risk of imminent bankruptcy
“our risk of imminent bankruptcy;”
SEC MD&A · May 13, 2026
No current revenues from drug candidates
“We are an early-stage development company and we currently do not generate any revenues from our drug candidates.”
SEC MD&A · March 31, 2026
TSX delisting deferral
“the Continued Listing Committee of the TSX had decided to defer its delisting decision until no later than April 17, 2026.”
SEC MD&A · March 31, 2026
Reduction in cash used in operations
“Our cash used in operating activities for the year ended December 31, 2025 and December 31, 2024 was $22.0 and $36.0 million, respectively, for a decrease of $14.0 million.”
SEC MD&A · March 31, 2026
Risks & what to watch (4)›
Key risks
- Imminent bankruptcy risk — Company has disclosed a risk of imminent bankruptcy and needs immediate funding [sec_mda · as of 2026-05-13].
- Negative shareholders' equity — Shareholders' deficit of $34.7M as of 2026-03-31 indicates financial distress [sec].
- TSX delisting uncertainty — TSX has deferred delisting decision; potential suspension or delisting of securities [sec_mda · as of 2026-03-31].
- No revenue generation — Company has no current revenues from drug candidates and relies on external financing [sec_mda · as of 2026-03-31].
What to watch
- Ability to secure substantial funding to continue operations and avoid bankruptcy [sec_mda · as of 2026-05-13].
- TSX delisting decision deadline on April 17, 2026 [sec_mda · as of 2026-03-31].
- Progress of the TUSCANY study for tuspetinib and any clinical data readouts [sec_mda · as of 2026-03-31].
- Any updates on strategic alternatives or partnerships [sec_mda · as of 2026-05-13].
Sources: SEC MD&A · Generated August 10, 2026 · How we verify sources →
Run Aptose Biosciences Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Aptose Biosciences Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Regulatory
Financials
Short Interest
as of May 20, 2026- % of float
- 2.6%
- Days to cover
- 0.1
- Shares short
- 53,154
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
APTOF short interestGovernance
Frequently asked questions
What is the AI investment thesis for Aptose Biosciences Inc.?
Aptose Biosciences Inc. is a clinical-stage biotechnology company developing targeted therapies for hematologic malignancies, currently facing severe liquidity constraints and a risk of imminent bankruptcy.
Who is the CEO of Aptose Biosciences Inc.?
Dr. William G. Rice Ph.D. is the chief executive officer of Aptose Biosciences Inc. (APTOF).
Where is Aptose Biosciences Inc. headquartered?
Aptose Biosciences Inc. (APTOF) is headquartered in Toronto, ON, Canada.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.